Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/20/2025

Ascites Management in Cirrhosis

Dietary and Pharmacological Interventions

  • The European Association for the Study of the Liver recommends a no-added salt diet limited to 90 mmol/day (5.2 g salt/day) for patients with ascites in cirrhosis 1, 2
  • The European Association for the Study of the Liver suggests starting with spironolactone alone (100 mg/day, increasing to 400 mg/day as needed) for diuretic therapy in patients with ascites in cirrhosis 1, 2
  • Furosemide (up to 160 mg/day) should be added to spironolactone if the latter alone is insufficient for patients with ascites in cirrhosis 1, 2
  • Current guidelines on ascites management do not specifically recommend SGLT2 inhibitors as primary therapy 1, 2

Therapeutic Paracentesis and TIPSS

  • The European Association for the Study of the Liver recommends therapeutic paracentesis as first-line treatment for patients with large or refractory ascites 2
  • For paracentesis >5L, albumin infusion (8g albumin/L of ascites removed) is required to prevent complications 2
  • For paracentesis <5L, albumin may be considered in patients with acute-on-chronic liver failure or high risk of post-paracentesis acute kidney injury 2
  • TIPSS (Transjugular Intrahepatic Portosystemic Shunt) should be considered in patients with refractory ascites, with caution needed in patients with age >70 years, bilirubin >50 μmol/L, platelet count <75×10^9/L, MELD score ≥18, current hepatic encephalopathy, active infection, or hepatorenal syndrome 2

SGLT2 Inhibitors as Adjunctive Therapy

  • SGLT2 inhibitors should be considered as adjunctive therapy to standard diuretic treatment, not as replacement, in patients with ascites in cirrhosis, particularly those with concurrent type 2 diabetes or heart failure 3
  • Caution is needed in patients with severe hyponatremia, as SGLT2 inhibitors may potentially worsen this condition 3

Monitoring and Follow-up

  • Patients on SGLT2 inhibitors should be monitored closely for electrolyte abnormalities, particularly hyponatremia, renal function, volume status, and blood pressure 3